Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
DomainIG

SIGLEC8 SPEG NEO1 NCAN

1.12e-03421214SM00409
DomainIg_sub

SIGLEC8 SPEG NEO1 NCAN

1.12e-03421214IPR003599
DomainIg_I-set

SIGLEC8 SPEG NEO1

1.20e-03190213IPR013098
DomainI-set

SIGLEC8 SPEG NEO1

1.20e-03190213PF07679
DomainIG_LIKE

SIGLEC8 SPEG NEO1 NCAN

1.98e-03491214PS50835
DomainIg-like_dom

SIGLEC8 SPEG NEO1 NCAN

2.16e-03503214IPR007110
DomainIGc2

SIGLEC8 SPEG NEO1

2.21e-03235213SM00408
DomainIg_sub2

SIGLEC8 SPEG NEO1

2.21e-03235213IPR003598
Domain-

SIGLEC8 SPEG NEO1 NCAN

5.82e-036632142.60.40.10
DomainIg-like_fold

SIGLEC8 SPEG NEO1 NCAN

7.25e-03706214IPR013783
Domainfn3

SPEG NEO1

1.41e-02162212PF00041
DomainV-set

SIGLEC8 NCAN

1.79e-02184212PF07686
DomainFN3

SPEG NEO1

1.81e-02185212SM00060
Pubmed

WDR76 is a RAS binding protein that functions as a tumor suppressor via RAS degradation.

UBE4B PLCH2

4.52e-045221230655611
GeneFamilyBlood group antigens|CD molecules|I-set domain containing|Immunoglobulin like domain containing

SPEG NEO1

7.67e-03161152593
GeneFamilyAdenosine receptors|V-set domain containing

SIGLEC8 NCAN

7.85e-03163152590
CoexpressionDARWICHE_PAPILLOMA_RISK_HIGH_DN

UBE4B SIGLEC8 MSI1 AFF3

1.81e-05201214MM500
CoexpressionDARWICHE_SQUAMOUS_CELL_CARCINOMA_DN

UBE4B SIGLEC8 MSI1 AFF3

1.81e-05201214MM502
CoexpressionDARWICHE_SKIN_TUMOR_PROMOTER_DN

UBE4B SIGLEC8 MSI1 AFF3

2.82e-05225214MM496
ToppCellPBMC-Severe-Lymphocyte-B-B_cell-B_naive-B_naive-13|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

NFKBID PROB1 AFF3

4.09e-05144213b2a9f3b5dd46d27689467f4a5fd717cd5827821f
ToppCellTuft-tuft-1|World / Class top

NFKBID PROB1 AFF3

6.47e-051682138ddc2ec483ed2c6c0fb2ae521c6861ceb6d32e34
ToppCell3'-GW_trimst-2-LargeIntestine-Hematopoietic-B_cells-Pre-B|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract

NFKBID PLCH2 AFF3

7.06e-0517321367c342295b8a06ce38e081ba74478c568917a396
ToppCellrenal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Degenerative_Vascular_Smooth_Muscle_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

PROB1 SPEG NCAN

7.06e-051732133001dd39244ef0a5a475d569a78f4ae427a55db6
ToppCellrenal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Degenerative_Vascular_Smooth_Muscle_Cell-|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

PROB1 SPEG NCAN

7.06e-05173213c88883fb2a33e21d4201aa393674aa3f2ad780c9
ToppCellSevere-B_naive-8|Severe / disease group and sub_cluster of B and Plasma cells(res = 0.5)

NFKBID PLCH2 AFF3

7.18e-05174213f3f8c924420f46321bd47e2b97f18c7241541599
ToppCell5'-GW_trimst-2-LargeIntestine-Hematopoietic-B_cells-Pre-B|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract

PROB1 PLCH2 AFF3

7.81e-05179213dc0b806904ef4c2f74f34ade2b1c0d6893f3b2ec
ToppCellfacs-Brain_Non-Myeloid-Striatum_-18m-Macroglial-oligodendrocyte_precursor_cell|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PRUNE2 AMPD3 NCAN

7.94e-05180213fa819df81fca95c2cc602fede635cb03e3f35fad
ToppCell18-Airway-Immune-Hematopoietic,_B_Cells|Airway / Age, Tissue, Lineage and Cell class

NFKBID SIGLEC8 AFF3

7.94e-05180213200cecbd8c12a4ec334583fdd5057397504de71e
ToppCellfacs-Brain_Non-Myeloid-Striatum_-18m-Macroglial-Oligodendrocyte_progenitor_cell|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PRUNE2 AMPD3 NCAN

7.94e-05180213907cd510fd2e21532ce04ba687e8894f7af71f27
ToppCellfacs-Brain_Non-Myeloid-Cortex_-18m-Macroglial-oligodendrocyte_precursor_cell|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PRUNE2 AMPD3 NCAN

8.48e-051842138d86e125257ff1d3af8d90577a8b3f0321eca21c
ToppCellfacs-Brain_Non-Myeloid-Cortex_-18m-Macroglial-Oligodendrocyte_progenitor_cell|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PRUNE2 AMPD3 NCAN

8.48e-05184213278a7ed764c326450cb70e69ed2175980eaf5fe0
ToppCellfacs-Trachea-nan-24m-Epithelial|Trachea / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PLCH2 DLEC1 MSLN

8.75e-051862136c06163d7315f1c71b15fe76f2e696bf3fa73b67
ToppCellfacs-Trachea-nan-24m-Epithelial-nan|Trachea / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PLCH2 DLEC1 MSLN

8.75e-0518621378e3b00eb347d1aa197671e31be9b0c6e4235760
ToppCell10x5'-Lung-Myeloid_Dendritic-DC2|Lung / Manually curated celltypes from each tissue

NFKBID MSLN AFF3

9.76e-05193213c97f9b13057f803df63c696c6175ef8e0aba6fa7
ToppCell10x5'-Lung-Myeloid_Dendritic|Lung / Manually curated celltypes from each tissue

NFKBID MSLN AFF3

9.76e-051932137bce609699c515d2d114596a0c527f90cc09c4af
ToppCellBAL-Control-Myeloid-cDC-cDC-cDC_5|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

NFKBID AMPD3 AFF3

9.91e-0519421336f8ae4f2b3bf802f6ff0e9fc79e7f170f96ae8b
ToppCell10x_3'_v2v3-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte-B|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

PRUNE2 PLCH2 ABCA2

1.04e-0419721382b8e22317cad6d3786bd70d91107007c0ccd7cd
ToppCellSmart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-TAM-MG-TAM-MG_aging_sig-F|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

NFKBID SIGLEC8 MSLN

1.07e-04199213b0a906586e58009f5ed9272fc29ba28e49c85ee6
ToppCell(3)_ILC|World / shred on Cell_type and subtype

NFKBID NEO1 AFF3

1.08e-0420021303554b3f323785b1e0b48fa32de0d92065dd798e
ToppCell10x_3'_v2v3-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte-F|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

PRUNE2 PLCH2 ABCA2

1.08e-042002133ce8a2db8c25e1169a0a544f644a63104749c5ee
ToppCell(30)_ILC|World / shred on Cell_type and subtype

NFKBID NEO1 AFF3

1.15e-04204213bd9fbd278c05e396463704d711b60d47699e3c09
ToppCellSevere-B_naive-13|Severe / disease group and sub_cluster of B and Plasma cells(res = 0.5)

NFKBID PROB1

1.34e-03116212f81a7c3e9cbf39124232d98e2a3a3e308137f391
ToppCellSevere-B_naive-13|World / disease group and sub_cluster of B and Plasma cells(res = 0.5)

NFKBID PROB1

1.43e-03120212d08edc09de8497714af55a6ca08a447cd71095e7
ToppCell3'_v3-bone_marrow-Lymphocytic_T_CD4-T_CD4/CD8|bone_marrow / Manually curated celltypes from each tissue

MUC17 MSI1

1.46e-0312121219333a660800b583fa27b495c1f7828e6636a257
ToppCellLPS-antiTNF-Stromal_mesenchymal-Myocytic-Myofibroblast|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

PRUNE2 SPEG

1.50e-0312321287401764a073c1808f214642a9c84299c78f7ec7
ToppCellLPS-antiTNF-Epithelial_alveolar-Mes-Like-Differentiating_AT1|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

SPEG ABCA2

1.63e-031282122cf0384240a4a663869cf6b27d954236f6214a9a
ToppCellPBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c02-AQP3|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)

PLCH2 MSI1

1.68e-03130212c63f402d6ab71c2fcef12174b3139e55a727266c
ToppCellPBMC-Severe-Lymphocyte-B-B_cell-B_intermediate-B_activate-7|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

NFKBID AFF3

1.73e-03132212c07842a4b514f1e950c8af303f3b6b4275906e6a
ToppCellhealthy_donor-Lymphocytic-T_cell-CD4+_T_cell_(ISG_high)|healthy_donor / Disease condition, Lineage, Cell class and subclass

SPEG GPRIN2

1.89e-0313821297f5dc17522462133e582b508ad0ef036e656872
ToppCellTCGA-Bladder-Solid_Tissue_Normal-Urothelial_normal_tissue-Urothelial_normal_tissue-2|TCGA-Bladder / Sample_Type by Project: Shred V9

PRUNE2 AFF3

1.97e-031412121baa054c2ae3b446d1954244b7fbf8af824ef345
ToppCellPBMC-Severe-Lymphocyte-B-B_cell-B_memory-B_activate-7|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

NFKBID AFF3

2.02e-031432124122dcb742d3c8deff552b4dae9f2d239e6828f3
ToppCellmild_COVID-19-B_cell|World / disease group, cell group and cell class (v2)

NFKBID AFF3

2.02e-031432124698cc877dda9b1ef7d6f18c9adc869ef791b1d8
ToppCellSevere-B_naive-8|World / disease group and sub_cluster of B and Plasma cells(res = 0.5)

PLCH2 AFF3

2.08e-03145212a24cad86509208bc7267b02ef1d1b0a25a2a7043
ToppCellHealthy-B_cell|World / disease group, cell group and cell class

NFKBID AFF3

2.11e-03146212588359d3df6ad7090b7fa6c7f8d29cc1717e7f4f
ToppCellPBMC-Severe-Lymphocyte-B-B_cell-B_naive-B_naive-9|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

NFKBID AFF3

2.22e-03150212d9931507257c64ead4a53786e6822f51962c6015
ToppCellBAL-Mild-Myeloid-cDC-cDC-cDC_3|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)

SIGLEC8 AMPD3

2.25e-031512120b6b37734430918378ed94e40877f0c4ae9b25ec
ToppCellBAL-Mild-Myeloid-cDC-cDC-cDC_3|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

SIGLEC8 AMPD3

2.25e-0315121230225a1a7800b0ae19e16ac164f561379eedb99d
ToppCellrenal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-Degenerative_Fibroblast-Degenerative_Fibroblast_104|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group

DLEC1 NCAN

2.25e-03151212ea62e92ccb984f44559b434f35c1c4450767c8f1
ToppCellChildren_(3_yrs)-Mesenchymal-airway_smooth_muscle_cell-D139|Children_(3_yrs) / Lineage, Cell type, age group and donor

PRUNE2 SPEG

2.31e-031532121524557514668f515ac1bbe847611f564b265b42
ToppCellfacs-Lung-18m-Hematologic-myeloid-leukocyte-proliferating_myeloid_cell|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

PLCH2 MSLN

2.31e-03153212596bb7cfd1c713708ce73df30d890a0233eae7f7
ToppCellfacs-Lung-18m-Hematologic-myeloid-leukocyte|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

PLCH2 MSLN

2.31e-031532128cc2667213bfac37545bb63181e88ef1f1834413
ToppCellHealthy-B_cell|Healthy / disease group, cell group and cell class

NFKBID AFF3

2.31e-031532127f82cd61b3f1ebaee3e4bbf68ba858a67c2065e7
ToppCellTransplant_Alveoli_and_parenchyma-Epithelial-Basal_2|Transplant_Alveoli_and_parenchyma / Tissue, Lineage and Cell class of Lung Cells from 10X

PLCH2 MSI1

2.31e-03153212a44da11a913b19edde6c5d1d6e625c24b20ecbfd
ToppCellLPS-IL1RA+antiTNF-Unknown-Endothelial-Myofibroblast|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

PRUNE2 SPEG

2.34e-0315421216fdafb5c64d2db321554f87129a962d113f1668
ToppCelltumor_Lymph_Node_/_Brain-B_lymphocytes-Undetermined|tumor_Lymph_Node_/_Brain / Location, Cell class and cell subclass

NFKBID PLCH2

2.34e-03154212e16f200391537aa1002b0079481b94e1fb86b9ad
ToppCellP28-Mesenchymal-mesenchymal_fibroblast-mesenchymal_progenitor_cell|P28 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

DLEC1 MSI1

2.34e-0315421244d4d99b08216c0901e3bc32743fa0a8b85b5149
ToppCellE16.5-samps-Epithelial-Alveolar_epithelial_precursor-Noncycling_AT1_Precursor|E16.5-samps / Age Group, Lineage, Cell class and subclass

PLCH2 MSLN

2.34e-031542128a643d91896af9b630a715fb284c1523d01ad1a3
ToppCellE18.5-samps-Endothelial-Mature_fetal_endothelial-capillary_endothelial_Hpgd-CA4_high|E18.5-samps / Age Group, Lineage, Cell class and subclass

PRUNE2 AFF3

2.34e-03154212212c340a096a3a9669d1aebd61c045cf1402a868
ToppCellPBMC-Mild-Myeloid-cDC-cDC-cDC_3|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

MSLN AFF3

2.37e-031552129a27558c457f05808af07190b7a5006b047f1d58
ToppCellPBMC-Mild-Myeloid-cDC-cDC-cDC_3|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)

MSLN AFF3

2.37e-03155212ab539c04f10276ae919d82b1c75f99a84eb695bf
ToppCellChildren_(3_yrs)-Mesenchymal-airway_smooth_muscle_cell-D032|Children_(3_yrs) / Lineage, Cell type, age group and donor

PRUNE2 SPEG

2.37e-03155212cd7d95cbcad248670e531d80bb83c55e36ebc573
ToppCell5'-Adult-Appendix-Hematopoietic-B_cells-Cycling_B_cell|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract

NFKBID AFF3

2.40e-03156212203ef22eb76bd2b829b027c30af0557080f4006c
ToppCellrenal_medulla_nuclei-Adult_normal_reference-Endothelial-blood_vessel_endothelial_cell_of_kidney-Degenerative_Endothelial_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

MUC17 PROB1

2.40e-03156212ea9223bb6450b22df11efa1705ab72dab005244a
ToppCellrenal_medulla_nuclei-Adult_normal_reference-Endothelial-blood_vessel_endothelial_cell_of_kidney-Degenerative_Endothelial_Cell-Degenerative_Peritubular_Capilary_Endothelial_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

MUC17 PROB1

2.40e-03156212586b5509074c4cc359e9e31a968c2ded71c994ca
ToppCellChildren_(3_yrs)-Mesenchymal-vascular_smooth_muscle_cell-D046|Children_(3_yrs) / Lineage, Cell type, age group and donor

PROB1 SPEG

2.46e-0315821284c0a215dabf697ada036c2b9592d0c61b5077de
ToppCell3'_v3-lymph-node_spleen-Lymphocytic_B-ABC_aged-B_naive|lymph-node_spleen / Manually curated celltypes from each tissue

DLEC1 AFF3

2.46e-031582127098847804dd90fa1dd74536e4e90f989b630fe4
ToppCell3'-Distal_airway-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)-Multiciliated_(non-nasal)_L.0.3.3.1|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

PRUNE2 DLEC1

2.49e-031592125543f5aec6352a7c5923e55daf3ed40ff5cc0f0c
ToppCellBronchial-10x5prime-Stromal-Myofibroblastic-Muscle_smooth_airway_ASM|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations

PRUNE2 SPEG

2.49e-031592127cda111bb98f1241989e49d490bdf51a712ea589
ToppCellTransplant_Alveoli_and_parenchyma-Epithelial-Ciliated_2|Epithelial / Tissue, Lineage and Cell class of Lung Cells from 10X

AMPD3 DLEC1

2.52e-031602126de505bfe1fbbe984718740a9cf43d0e02ff452e
ToppCellfacs-Lung-EPCAM-18m-Hematologic-Proliferating_Immune|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PLCH2 MSLN

2.52e-031602127217730ae14840b935b3bf9aa49becbcbcd8a682
ToppCellfacs-Lung-EPCAM-18m-Hematologic|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PLCH2 MSLN

2.52e-03160212317ef81460c1a31b51119a6309b11be6a8d4ea3e
ToppCellfacs-Lung-EPCAM-18m-Hematologic-leukocyte|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PLCH2 MSLN

2.52e-03160212e6191240c93da34fc4431a35ef496edf323cb41e
ToppCellmild_COVID-19_(asymptomatic)-B_intermediate|World / disease group, cell group and cell class (v2)

NFKBID AFF3

2.52e-031602126722934e153b72039c3c4308557d0ef879a30638
ToppCellAdult-Mesenchymal-airway_smooth_muscle_cell-D231|Adult / Lineage, Cell type, age group and donor

PRUNE2 SPEG

2.52e-03160212d783d29150033e9181c0e30870070268fed3fd85
ToppCellAdult-Mesenchymal-airway_smooth_muscle_cell-D122|Adult / Lineage, Cell type, age group and donor

PRUNE2 SPEG

2.56e-0316121264891f6f2ee1693c8481e951b9346e2f92d602e3
ToppCellBAL-Severe-Myeloid-cDC-cDC-cDC_8|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)

NFKBID AFF3

2.56e-031612127e0b8119cea208c0b4a0dffdf94ff6137d0b4c90
ToppCellPBMC_fresh-frozen-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_B-B_cell-B_c03-CD27-AIM2|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)

NFKBID AFF3

2.56e-0316121263f0b97c741b610c450f65fa5764d712bfe09ce8
ToppCell390C-Lymphocytic-NK_cells-NK_cell_D|390C / Donor, Lineage, Cell class and subclass (all cells)

NFKBID NCAN

2.56e-03161212b60b4fd34a3ad4bf1813e6cc24aa7e04f9e53e4c
ToppCellLPS-IL1RA-Epithelial_airway|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

DLEC1 MSLN

2.56e-03161212472c354f5ee148b37a5dfb795e83348ecb1643f1
ToppCellTCGA-Brain-Primary_Tumor-Low_Grade_Glioma-Astrocytoma|TCGA-Brain / Sample_Type by Project: Shred V9

SIGLEC8 PROB1

2.59e-03162212810881210e015c788814e4fe8d7a24c929cf2621
ToppCellBAL-Severe-Myeloid-cDC-cDC-cDC_8|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

NFKBID AFF3

2.59e-031622122fd6e8f48b48d509a7533cec2f79089513c34a2f
ToppCellPBMC-Mild-Lymphocyte-B-B_cell-B_naive-B_naive-13|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

NFKBID AFF3

2.59e-0316221228b3a6ae5519a267eefb70436d3190a387d027b9
ToppCell10x5'-Liver-Lymphocytic_Invariant-Inducer-like-ILC3|Liver / Manually curated celltypes from each tissue

NEO1 AFF3

2.62e-031632127f61483eeb1fde21843c6391468e13cb0cc2a89f
ToppCellHealthy_Control-Lymphoid-B-|Healthy_Control / Condition, Lineage, Cell class and cell subclass

PLCH2 AFF3

2.62e-03163212d84bd41b4494c7d5c7f88d511bfe481fb12f079d
ToppCellInfluenza_Severe-NK_CD56bright|Influenza_Severe / Disease group and Cell class

PLCH2 NEO1

2.62e-031632127748d5709e8cf6673f5a8370108309f76cd830f4
ToppCellTransplant_Alveoli_and_parenchyma-Epithelial-Basal_2|Epithelial / Tissue, Lineage and Cell class of Lung Cells from 10X

PLCH2 MSI1

2.62e-03163212f21951e63188eb0c04675a8f81a0da495c26c007
ToppCellfacs-Lung-3m-Hematologic-myeloid-classical_monocyte-classical_monocyte_l15|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

PRUNE2 ECE2

2.62e-03163212f558ad9569e5137e62a601ba4f073e69ed8f8650
ToppCellPBMC_fresh-frozen-Mild-Moderate_progression_d02_child-Lymphocytic-Lymphocytic_B|Mild-Moderate_progression_d02_child / Compartment, severity and other cell annotations on 10x 3' data (130k)

NFKBID AFF3

2.62e-031632126bed27d2f67a430a847da5eb47878d14b4949c45
ToppCell343B-Lymphocytic-NK_cells-NK_cell_D3|343B / Donor, Lineage, Cell class and subclass (all cells)

NFKBID PLCH2

2.62e-031632128a4931c9fdaedcf6c319157821d3556cd25fc9e5
ToppCellHealthy_Control-Lymphoid-B|Healthy_Control / Condition, Lineage, Cell class and cell subclass

PLCH2 AFF3

2.62e-031632120f723ec2503afa1b3ebb0754972438ffb6e6179d
ToppCell10x3'2.3-week_14-16-Lymphocytic_B-B_lineage-immature_B_cell|week_14-16 / cell types per 3 fetal stages;per 3',per 5'

NFKBID AFF3

2.65e-0316421269b6566fb88c7449b7ab9056b57508cb6a1aa2af
ToppCellPBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_T-CD8-positive,_mature_gamma-delta_T_cell-T_gdT_c14-TRDV2|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)

SIGLEC8 NEO1

2.65e-03164212ed7277f8980f96f5b3e4eed025d46d0942e123d7
ToppCellfacs-Lung-EPCAM-24m-Myeloid-lung_macrophage|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PRUNE2 SPEG

2.65e-031642124e0133a7f80cf6bd3d70f72ee26360df5f80ab32
ToppCellPBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_T-CD8-positive,_mature_gamma-delta_T_cell|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)

SIGLEC8 NEO1

2.65e-03164212c4ad98106e8663caf7c1c15d30ec633d8bd8cf57
ToppCellLPS-antiTNF-Epithelial_airway-Mes-Epi-like|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

MSI1 GPRIN2

2.65e-031642124307b002fb41ddfc7ab8a6bca66a60942c250052
ToppCellfacs-Marrow-KLS-24m-Lymphocytic|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

UBE4B GPRIN2

2.65e-03164212d2b5f51af7fcffddebe997ee302bacbd85d76852
ToppCellfacs-Lung-EPCAM-24m-Myeloid-Interstitial_Macrophage|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PRUNE2 SPEG

2.65e-031642124ab1a7d5379a633c3f61af1c8c2df93b6961d9cf
ToppCellChildren_(3_yrs)-Mesenchymal-airway_smooth_muscle_cell-D046|Children_(3_yrs) / Lineage, Cell type, age group and donor

PRUNE2 SPEG

2.65e-03164212e3983f655cdba308fb192182829f17bef99ce0ba
ToppCellLPS-antiTNF-Epithelial_airway-Mes-Epi-like-Airway|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

MSI1 GPRIN2

2.65e-031642121d84aa5b925f502ee9c5fa39714490f613a58028
ToppCellMild-MAIT|World / Disease group and Cell class

PRUNE2 AFF3

2.65e-0316421221dc02997dfae73cf70ce291661928526605dba1
ToppCellrenal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-glomerular_mesenchymal_cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group

PROB1 NEO1

2.68e-03165212e2aebb2fe197151e019371b8960f76f0c2386f08
ToppCell15-Airway-Mesenchymal-Airway_Smooth_Muscle|Airway / Age, Tissue, Lineage and Cell class

PRUNE2 SPEG

2.68e-03165212531804467601e1ee1f771cffa21501f6d464ae10
ToppCellrenal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group

PROB1 NEO1

2.68e-03165212b087771499aeb31cc4a338d2d0a9392a4ec1ac45
ToppCellrenal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell-mesangial_typical-aged|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group

PROB1 NEO1

2.68e-03165212d8f8b088fd28a6b9dbd6b51bcaee42000e963321
ToppCellInfluenza_Severe-B_memory|Influenza_Severe / Disease group and Cell class

NFKBID AFF3

2.68e-0316521251172acaeb667b34b8b8c7878d67cfa0c4a2dffc
ToppCellmild_COVID-19_(asymptomatic)-B_intermediate|mild_COVID-19_(asymptomatic) / disease group, cell group and cell class (v2)

NFKBID AFF3

2.71e-031662128de8f388f24436b84e19ef460476fdbda4d16abf
ToppCellnormal_Lung-Myeloid_cells-CD163+CD14+_DCs|Myeloid_cells / Location, Cell class and cell subclass

NFKBID AMPD3

2.71e-0316621207b498eb341abec02a3ccaae320bdbb5cd6883c5
ToppCellfacs-Brain_Non-Myeloid-Striatum-3m-Neuronal-neuron|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

DLEC1 AFF3

2.71e-03166212548d0d6c0ffd564036ddba78620734220ebb73d7
ToppCellfacs-Brain_Non-Myeloid-Striatum-3m-Neuronal-nan|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

DLEC1 AFF3

2.71e-0316621280e164a89d22098cabe4a99a78283ba69ea0561e
ComputationalAdhesion molecules.

NEO1 NCAN MSLN

4.46e-04141123MODULE_122
DrugDeltaline [6836-11-9]; Down 200; 7.8uM; HL60; HT_HG-U133A

AMPD3 ABCA2 BAG4 AFF3

2.90e-051972142171_DN
DrugRoxarsone [121-19-7]; Up 200; 15.2uM; PC3; HT_HG-U133A

PLCH2 NEO1 MSLN GPRIN2

2.90e-051972145051_UP
Drugestradiol, USP; Up 200; 0.01uM; MCF7; HT_HG-U133A

SIGLEC8 AMPD3 ABCA2 MSI1

2.96e-051982146957_UP
DrugMafenide hydrochloride [138-37-4]; Up 200; 18uM; PC3; HT_HG-U133A

PRUNE2 ABCA2 GPRIN2 AFF3

3.02e-051992145079_UP
Drugcobalt(II) chloride hexahydrate; Up 200; 100uM; MCF7; HG-U133A

PRUNE2 AMPD3 ECE2 GPRIN2

3.02e-05199214454_UP
DrugBenoxinate hydrochloride [5987-82-6]; Up 200; 11.6uM; MCF7; HT_HG-U133A

SIGLEC8 SPEG PLCH2 GPRIN2

3.02e-051992144115_UP
Drugchloroprocaine

MSLN SHKBP1

9.65e-0516212CID000008612
DrugEtilefrine hydrochloride [534-87-2]; Up 200; 18.4uM; HL60; HT_HG-U133A

AMPD3 ABCA2 GPRIN2

5.91e-041812132930_UP
DrugChlorpromazine hydrochloride [69-09-0]; Up 200; 11.2uM; MCF7; HT_HG-U133A

UBE4B AMPD3 GPRIN2

6.60e-041882135493_UP
DrugIvermectin [70288-86-7]; Up 200; 4.6uM; MCF7; HT_HG-U133A

MSI1 GPRIN2 BAG4

6.71e-041892137206_UP
DrugAlexidine dihydrochloride [22573-93-9]; Down 200; 6.8uM; PC3; HT_HG-U133A

UBE4B SPEG BAG4

6.91e-041912137397_DN
DrugOrlistat; Up 200; 10uM; PC3; HT_HG-U133A

SIGLEC8 AMPD3 MSI1

7.02e-041922136388_UP
DrugEtofenamate [30544-47-9]; Up 200; 10.8uM; MCF7; HT_HG-U133A

AMPD3 PLCH2 GPRIN2

7.02e-041922134108_UP
DrugMethylhydantoin-5-(L) [40856-73-3]; Down 200; 35uM; MCF7; HT_HG-U133A

AMPD3 ABCA2 GPRIN2

7.13e-041932133378_DN
DrugAspartic acid, N-acetyl (R,S) [997-55-7]; Up 200; 22.8uM; MCF7; HT_HG-U133A

SIGLEC8 AMPD3 AFF3

7.13e-041932134125_UP
DrugMianserine hydrochloride [21535-47-7]; Up 200; 13.2uM; PC3; HT_HG-U133A

SIGLEC8 ABCA2 BAG4

7.23e-041942132068_UP
DrugSulfanilamide [63-74-1]; Up 200; 23.2uM; PC3; HT_HG-U133A

SIGLEC8 AMPD3 ABCA2

7.23e-041942134474_UP
DrugNystatine [1400-61-9]; Up 200; 4.4uM; PC3; HT_HG-U133A

SIGLEC8 AMPD3 MSI1

7.23e-041942134223_UP
DrugKawain [500-64-1]; Up 200; 17.4uM; MCF7; HT_HG-U133A

SIGLEC8 SPEG MSI1

7.23e-041942132299_UP
DrugPhenacetin [62-44-2]; Up 200; 22.4uM; MCF7; HT_HG-U133A

AMPD3 MSI1 GPRIN2

7.34e-041952134111_UP
DrugReserpinic acid hydrochloride; Up 200; 9.2uM; MCF7; HT_HG-U133A

PRUNE2 SIGLEC8 MSI1

7.34e-041952137323_UP
DrugCimetidine [51481-61-9]; Up 200; 15.8uM; PC3; HT_HG-U133A

PRUNE2 SIGLEC8 MSLN

7.34e-041952134063_UP
DrugGlipizide [29094-61-9]; Up 200; 9uM; MCF7; HT_HG-U133A

PRUNE2 SIGLEC8 MSI1

7.34e-041952134991_UP
Drugrapamycin, Streptomyces hygroscepicus; Down 200; 0.1uM; PC3; HT_HG-U133A

SIGLEC8 ABCA2 MSI1

7.34e-041952135980_DN
Drug(S)-propranolol hydrochloride [4199-10-4]; Up 200; 13.6uM; MCF7; HT_HG-U133A

MSI1 BAG4 AFF3

7.34e-041952135444_UP
Drug5286656; Up 200; 50uM; MCF7; HT_HG-U133A_EA

PRUNE2 AMPD3 ABCA2

7.34e-04195213889_UP
DrugMethoxamine hydrochloride [61-16-5]; Down 200; 16.2uM; HL60; HT_HG-U133A

UBE4B ABCA2 BAG4

7.45e-041962132488_DN
DrugAtractyloside potassium salt [102130-43-8]; Up 200; 5uM; MCF7; HT_HG-U133A

AMPD3 NEO1 GPRIN2

7.45e-041962133435_UP
DrugCarcinine [56897-53-1]; Up 200; 22uM; PC3; HT_HG-U133A

SIGLEC8 PLCH2 NCAN

7.45e-041962134225_UP
DrugCGX 0596987; Up 200; 20uM; MCF7; HT_HG-U133A

AMPD3 SPEG GPRIN2

7.45e-041962136364_UP
DrugSolanine alpha [20562-02-1]; Up 200; 4.6uM; PC3; HT_HG-U133A

SIGLEC8 ABCA2 AFF3

7.45e-041962134087_UP
DrugKawain [500-64-1]; Down 200; 17.4uM; PC3; HT_HG-U133A

UBE4B SPEG BAG4

7.45e-041962137369_DN
DrugSulfamethazine sodium salt [1981-58-4]; Up 200; 13.4uM; HL60; HT_HG-U133A

PRUNE2 DLEC1 NCAN

7.45e-041962132560_UP
DrugMetoclopramide monohydrochloride [7232-21-5]; Down 200; 11.8uM; MCF7; HT_HG-U133A

AMPD3 ABCA2 GPRIN2

7.45e-041962132315_DN
Drughaloperidol; Down 200; 10uM; HL60; HT_HG-U133A

ABCA2 GPRIN2 AFF3

7.45e-041962136203_DN
DrugChlorpropamide [94-20-2]; Up 200; 14.4uM; MCF7; HT_HG-U133A

PRUNE2 PLCH2 BAG4

7.45e-041962133210_UP
DrugEtodolac [41340-25-4]; Up 200; 14uM; MCF7; HT_HG-U133A

UBE4B AMPD3 ABCA2

7.45e-041962132254_UP
DrugPentetic acid [67-43-6]; Down 200; 10.2uM; HL60; HT_HG-U133A

ABCA2 GPRIN2 AFF3

7.45e-041962133049_DN
DrugTalampicillin hydrochloride [39878-70-1]; Up 200; 7.8uM; HL60; HT_HG-U133A

AMPD3 ABCA2 AFF3

7.56e-041972132954_UP
DrugAdrenosterone [382-45-6]; Up 200; 13.4uM; PC3; HT_HG-U133A

PRUNE2 ABCA2 MSI1

7.56e-041972135045_UP
DrugEthambutol dihydrochloride [1070-11-7]; Up 200; 14.4uM; MCF7; HT_HG-U133A

AMPD3 SPEG GPRIN2

7.56e-041972134120_UP
DrugGuanabenz acetate [23256-50-0]; Up 200; 13.8uM; MCF7; HT_HG-U133A

PRUNE2 SIGLEC8 ABCA2

7.56e-041972135703_UP
DrugPivampicillin [33817-20-8]; Up 200; 8.6uM; PC3; HT_HG-U133A

AMPD3 SPEG GPRIN2

7.56e-041972135046_UP
DrugBretylium tosylate [61-75-6]; Down 200; 9.6uM; MCF7; HT_HG-U133A

AMPD3 SPEG MSI1

7.56e-041972133394_DN
DrugLithocholic acid [434-13-9]; Up 200; 10.6uM; MCF7; HT_HG-U133A

AMPD3 PLCH2 GPRIN2

7.56e-041972133899_UP
DrugTinidazole [19387-91-8]; Up 200; 16.2uM; HL60; HT_HG-U133A

PRUNE2 SIGLEC8 NCAN

7.56e-041972132568_UP
DrugAminohippuric acid [61-78-9]; Down 200; 20.6uM; MCF7; HT_HG-U133A

UBE4B AMPD3 GPRIN2

7.56e-041972136453_DN
DrugCyclopenthiazide [742-20-1]; Up 200; 10.6uM; PC3; HT_HG-U133A

PRUNE2 SIGLEC8 AFF3

7.56e-041972134229_UP
DrugMyosmine [532-12-7]; Up 200; 27.4uM; MCF7; HT_HG-U133A

AMPD3 MSLN GPRIN2

7.56e-041972136055_UP
DrugGlycopyrrolate [596-51-0]; Down 200; 10uM; PC3; HT_HG-U133A

UBE4B SPEG BAG4

7.56e-041972137386_DN
DrugSertaconazole nitrate [99592-39-9]; Up 200; 8uM; MCF7; HT_HG-U133A

SIGLEC8 SPEG ABCA2

7.68e-041982133550_UP
DrugEthamivan [304-84-7]; Down 200; 18uM; MCF7; HT_HG-U133A

AMPD3 ABCA2 GPRIN2

7.68e-041982132879_DN
DrugQuinethazone [73-49-4]; Up 200; 13.8uM; PC3; HT_HG-U133A

PRUNE2 ABCA2 AFF3

7.68e-041982134529_UP
DrugDimenhydrinate [523-87-5]; Up 200; 8.6uM; PC3; HT_HG-U133A

PRUNE2 UBE4B GPRIN2

7.68e-041982136352_UP
DrugMycophenolic acid [24280-93-1]; Up 200; 12.4uM; PC3; HT_HG-U133A

SIGLEC8 NEO1 ABCA2

7.68e-041982134019_UP
DrugZoxazolamine [61-80-3]; Up 200; 23.8uM; PC3; HT_HG-U133A

NCAN MSLN GPRIN2

7.68e-041982136290_UP
DrugChlorzoxazone [95-25-0]; Down 200; 23.6uM; PC3; HT_HG-U133A

UBE4B SPEG BAG4

7.68e-041982132100_DN
DrugMinaprine dihydrochloride [25953-17-7]; Up 200; 10.8uM; PC3; HT_HG-U133A

PRUNE2 SIGLEC8 NCAN

7.68e-041982134230_UP
DrugFenofibrate [49562-28-9]; Down 200; 11uM; HL60; HT_HG-U133A

UBE4B GPRIN2 BAG4

7.68e-041982132401_DN
DrugRifampicin [13292-46-1]; Down 200; 4.8uM; MCF7; HT_HG-U133A

AMPD3 ABCA2 BAG4

7.68e-041982132847_DN
DrugFlufenamic acid [530-78-9]; Up 200; 14.2uM; PC3; HT_HG-U133A

SIGLEC8 AMPD3 GPRIN2

7.68e-041982135059_UP
DrugNovobiocin sodium salt [1476-53-5]; Down 200; 6.4uM; PC3; HT_HG-U133A

SPEG ABCA2 GPRIN2

7.68e-041982134569_DN
DrugPropidium iodide [25535-16-4]; Down 200; 6uM; MCF7; HT_HG-U133A

AMPD3 ABCA2 GPRIN2

7.68e-041982136104_DN
DrugDextromethorphan hydrobromide monohydrate [6700-34-1]; Up 200; 10.8uM; MCF7; HT_HG-U133A

SIGLEC8 AMPD3 SPEG

7.68e-041982132636_UP
DrugSC-58125; Up 200; 10uM; MCF7; HG-U133A

AMPD3 SPEG PLCH2

7.79e-04199213254_UP
DrugKetoprofen [22071-15-4]; Up 200; 15.8uM; HL60; HT_HG-U133A

SIGLEC8 ABCA2 AFF3

7.79e-041992132354_UP
Drugrapamycin; Down 200; 0.1uM; ssMCF7; HG-U133A

SPEG DLEC1 ECE2

7.79e-04199213402_DN
Drugclozapine; Up 200; 10uM; MCF7; HG-U133A

AMPD3 SPEG DLEC1

7.79e-04199213416_UP
DrugLeflunomide [75706-12-6]; Down 200; 14.8uM; HL60; HT_HG-U133A

AMPD3 GPRIN2 AFF3

7.79e-041992132539_DN
DrugDipyrone [5907-38-0]; Up 200; 12uM; MCF7; HT_HG-U133A

SIGLEC8 ABCA2 GPRIN2

7.79e-041992133835_UP
DrugNomifensine maleate [32795-47-4]; Down 200; 11.2uM; MCF7; HT_HG-U133A

AMPD3 ABCA2 MSI1

7.79e-041992132224_DN
DrugKawain [500-64-1]; Up 200; 17.4uM; HL60; HT_HG-U133A

PRUNE2 UBE4B SIGLEC8

7.79e-041992132337_UP
DrugS(+)-Terguride [37686-84-3]; Up 200; 11.8uM; MCF7; HT_HG-U133A

SIGLEC8 PLCH2 ABCA2

7.79e-041992136459_UP
DrugConessine [546-06-5]; Up 200; 11.2uM; MCF7; HT_HG-U133A

AMPD3 SPEG GPRIN2

7.79e-041992134777_UP
DrugBuflomedil hydrochloride [35543-24-9]; Up 200; 11.6uM; MCF7; HT_HG-U133A

SIGLEC8 AMPD3 SPEG

7.79e-041992133274_UP
DrugLincomycin hydrochloride [859-18-7]; Up 200; 9uM; MCF7; HT_HG-U133A

SIGLEC8 SPEG ABCA2

7.79e-041992135992_UP
DrugN-Acetyl-DL-homocysteine Thiolactone [1195-16-0]; Up 200; 25.2uM; PC3; HT_HG-U133A

PRUNE2 ABCA2 MSLN

7.79e-041992134311_UP
DrugMepenzolate bromide [76-90-4]; Up 200; 9.6uM; MCF7; HT_HG-U133A

PRUNE2 AMPD3 SPEG

7.79e-041992136024_UP
DrugCP-690334-01 [459212-38-5]; Down 200; 1uM; PC3; HT_HG-U133A

AMPD3 SPEG GPRIN2

7.79e-041992134561_DN
DrugGuanadrel sulfate [22195-34-2]; Up 200; 7.6uM; HL60; HT_HG-U133A

PRUNE2 SPEG GPRIN2

7.90e-042002132575_UP
DrugStachydrine hydrochloride; Up 200; 22.2uM; PC3; HT_HG-U133A

PRUNE2 SIGLEC8 AMPD3

7.90e-042002134469_UP
DrugButacaine [149-16-6]; Up 200; 13uM; MCF7; HT_HG-U133A

DLEC1 ABCA2 BAG4

7.90e-042002136225_UP
DrugFlecainide acetate [54143-56-5]; Up 200; 8.4uM; MCF7; HT_HG-U133A

AMPD3 SPEG PLCH2

7.90e-042002133418_UP
DrugXylazine [7361-61-7]; Up 200; 18.2uM; MCF7; HT_HG-U133A

SIGLEC8 SPEG ABCA2

7.90e-042002132788_UP
DrugNoscapine [128-62-1]; Up 200; 9.6uM; MCF7; HT_HG-U133A

SPEG MSI1 BAG4

7.90e-042002137204_UP
DrugCondelphine [7633-69-4]; Up 200; 8.8uM; MCF7; HT_HG-U133A

SIGLEC8 AMPD3 GPRIN2

7.90e-042002133538_UP
DrugBetazole hydrochloride; Up 200; 27uM; MCF7; HT_HG-U133A

ABCA2 GPRIN2 AFF3

7.90e-042002135445_UP
Diseasechronic obstructive pulmonary disease

AMPD3 SPEG DLEC1 AFF3

8.59e-04688194EFO_0000341
Diseasedentures

PRUNE2 NEO1

9.24e-0470192EFO_0010078
Diseasedental caries, dentures

PRUNE2 NEO1

9.24e-0470192EFO_0003819, EFO_0010078
Diseaseapolipoprotein A 1 measurement

MUC17 AMPD3 DLEC1 AFF3

1.86e-03848194EFO_0004614
Diseasepancreatic cancer (is_marker_for)

MSLN BAG4

1.91e-03101192DOID:1793 (is_marker_for)
Diseaseretinal vasculature measurement

MUC17 AMPD3 AFF3

4.20e-03517193EFO_0010554
Diseaseneuroimaging measurement

PRR23A AMPD3 NEO1 AFF3

4.30e-031069194EFO_0004346
Diseasewaist-hip ratio

PRUNE2 AMPD3 DLEC1 AFF3

6.97e-031226194EFO_0004343
DiseaseFEV/FEC ratio

AMPD3 SPEG DLEC1 AFF3

7.01e-031228194EFO_0004713

Protein segments in the cluster

PeptideGeneStartEntry
MGGRYPWPSSAPSAP

BAG4

251

O95429
PWGASGKSTGTPSPM

AFF3

1106

P51826
WKGPPAASPAMSPTT

AMPD3

96

Q01432
MEAGPWRVSAPPSGP

NFKBID

1

Q8NI38
PGMTPGTPRSSGLFW

ECE2

56

P0DPD6
GPPYGPPSTWSVSTM

MSLN

231

Q13421
TGSHPWTMAPPPGST

MSI1

286

O43347
WTMAPPPGSTPSRTG

MSI1

291

O43347
PPTAGPEMWTSAPSL

ABCA2

1616

Q9BZC7
MSSSRPEPGPWAPLS

GPRIN2

1

O60269
GTMWAPTSPPAGSSS

DLEC1

21

Q9Y238
TPSRWPSPSPTAMPS

MENT

181

Q9BUN1
PVTPEGTTMPIWTPS

MUC17

3676

Q685J3
GTTMPIWTPSEGSTP

MUC17

3681

Q685J3
SGRSPTAMPEPWGNP

PRUNE2

771

Q8WUY3
MGSRPRSPSAFPAPW

PRR23A

1

A6NEV1
PTPGDPMLASWPTGE

NCAN

431

O14594
PGSPWPIGTSMSLSD

NEO1

1281

Q92859
WPSSGLGTPLTPPKM

SHKBP1

686

Q8TBC3
PPMISWIGASVSSPG

SIGLEC8

186

Q9NYZ4
PWLPSAMEGPTPVSA

MT-ND5

231

P03915
PSPQETWDPMGPGSS

PROB1

516

E7EW31
MGWRFPSPSPRQASP

nan

1

Q6ZSR3
GETWPRTPTMKPSPS

SPEG

841

Q15772
MSGPWPSPDSRTKGT

PLCH2

1

O75038
PAPTPSFWSSVPVMG

UBE4B

276

O95155